News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
676,483 Results
Type
Article (55575)
Company Profile (655)
Press Release (620253)
Multimedia
Podcasts (84)
Webinars (8)
Section
Business (185469)
Career Advice (2567)
Deals (33547)
Drug Delivery (98)
Drug Development (75066)
Employer Resources (132)
FDA (15970)
Job Trends (15638)
News (318340)
Policy (31090)
Tag
Academia (2800)
Academic (1)
Accelerated approval (5)
Adcomms (17)
Allergies (92)
Alliances (45123)
ALS (104)
Alzheimer's disease (1411)
Antibody-drug conjugate (ADC) (134)
Approvals (15976)
Artificial intelligence (277)
Autoimmune disease (26)
Automation (16)
Bankruptcy (289)
Best Places to Work (12311)
BIOSECURE Act (18)
Biosimilars (92)
Biotechnology (454)
Bladder cancer (81)
Brain cancer (29)
Breast cancer (300)
Cancer (2370)
Cardiovascular disease (185)
Career advice (2126)
Career pathing (29)
CAR-T (162)
Cell therapy (458)
Cervical cancer (22)
Clinical research (61087)
Collaboration (895)
Company closure (1)
Compensation (579)
Complete response letters (18)
COVID-19 (2420)
CRISPR (46)
C-suite (266)
Cystic fibrosis (107)
Data (2373)
Decentralized trials (1)
Denatured (9)
Depression (51)
Diabetes (261)
Diagnostics (6679)
Digital health (20)
Diversity (4)
Diversity, equity & inclusion (26)
Drug discovery (124)
Drug pricing (99)
Drug shortages (22)
Duchenne muscular dystrophy (96)
Earnings (73982)
Editorial (42)
Employer branding (19)
Employer resources (114)
Events (111749)
Executive appointments (792)
FDA (17401)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (8)
Funding (804)
Gene editing (114)
Generative AI (21)
Gene therapy (326)
GLP-1 (683)
Government (4302)
Grass and pollen (6)
Guidances (157)
Healthcare (20315)
Huntington's disease (22)
IgA nephropathy (27)
Immunology and inflammation (124)
Indications (29)
Infectious disease (2565)
Inflammatory bowel disease (152)
Inflation Reduction Act (8)
Influenza (53)
Intellectual property (101)
Interviews (439)
IPO (16737)
IRA (43)
Job creations (3842)
Job search strategy (1848)
Kidney cancer (10)
Labor market (35)
Layoffs (450)
Leadership (18)
Legal (6929)
Liver cancer (76)
Lung cancer (326)
Lymphoma (155)
Machine learning (9)
Management (49)
Manufacturing (339)
MASH (74)
Medical device (14246)
Medtech (14250)
Mergers & acquisitions (17468)
Metabolic disorders (677)
Multiple sclerosis (85)
NASH (22)
Neurodegenerative disease (98)
Neuropsychiatric disorders (27)
Neuroscience (1994)
NextGen: Class of 2025 (7328)
Non-profit (4959)
Now hiring (24)
Obesity (342)
Opinion (245)
Ovarian cancer (81)
Pain (105)
Pancreatic cancer (89)
Parkinson's disease (154)
Partnered (19)
Patents (245)
Patient recruitment (119)
Peanut (49)
People (55269)
Pharmaceutical (132)
Pharmacy benefit managers (16)
Phase I (18941)
Phase II (26574)
Phase III (20620)
Pipeline (1365)
Policy (149)
Postmarket research (2484)
Preclinical (8255)
Press Release (68)
Prostate cancer (109)
Psychedelics (31)
Radiopharmaceuticals (265)
Rare diseases (388)
Real estate (6326)
Recruiting (56)
Regulatory (22055)
Reports (34)
Research institute (2524)
Resumes & cover letters (415)
Rett syndrome (6)
RNA editing (4)
RSV (38)
Schizophrenia (77)
Series A (138)
Series B (93)
Service/supplier (25)
Sickle cell disease (53)
Special edition (18)
Spinal muscular atrophy (135)
Sponsored (24)
Startups (3496)
State (2)
Stomach cancer (10)
Supply chain (72)
Tariffs (51)
The Weekly (73)
Vaccines (646)
Venture capitalists (40)
Weight loss (213)
Women's health (25)
Worklife (13)
Date
Today (182)
Last 7 days (1027)
Last 30 days (3249)
Last 365 days (34013)
2025 (12434)
2024 (36624)
2023 (41389)
2022 (51564)
2021 (56186)
2020 (55973)
2019 (49797)
2018 (37212)
2017 (31876)
2016 (30598)
2015 (35988)
2014 (28825)
2013 (28474)
2012 (24993)
2011 (25254)
2010 (23711)
Location
Africa (843)
Alabama (58)
Alaska (6)
Arizona (177)
Arkansas (14)
Asia (39510)
Australia (7088)
California (6620)
Canada (2064)
China (563)
Colorado (281)
Connecticut (308)
Delaware (166)
Europe (90324)
Florida (980)
Georgia (226)
Hawaii (1)
Idaho (60)
Illinois (582)
India (27)
Indiana (340)
Iowa (11)
Japan (174)
Kansas (108)
Kentucky (28)
Louisiana (15)
Maine (71)
Maryland (983)
Massachusetts (5089)
Michigan (249)
Minnesota (433)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (25)
Nevada (69)
New Hampshire (69)
New Jersey (1867)
New Mexico (27)
New York (1867)
North Carolina (1141)
North Dakota (9)
Northern California (2878)
Ohio (225)
Oklahoma (15)
Oregon (48)
Pennsylvania (1465)
Puerto Rico (14)
Rhode Island (36)
South America (1163)
South Carolina (26)
South Dakota (1)
Southern California (2469)
Tennessee (107)
Texas (983)
United States (25199)
Utah (196)
Virginia (175)
Washington D.C. (66)
Washington State (615)
West Virginia (3)
Wisconsin (72)
676,483 Results for "new wave surgical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
Wave’s Duchenne Exon-Skipper Reverses Muscle Damage in Mid-Stage Trial
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II FORWARD-53 trial. Wave plans to file for accelerated approval of the candidate in 2026.
March 26, 2025
·
3 min read
·
Heather McKenzie
Duchenne muscular dystrophy
Safety Questions Loom in Duchenne as Dyne, Wave and Others Plan FDA Filings
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.
March 27, 2025
·
8 min read
·
Heather McKenzie
Job Trends
Massive Investment in US Manufacturing Triggers Wave of Career Opportunities
Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca executive and Eli Lilly and Novo Nordisk spokespeople discuss potential job and skill-building opportunities and where manufacturing might head in the future.
April 24, 2025
·
6 min read
·
Angela Gabriel
Press Releases
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 8, 2025
·
19 min read
Press Releases
SONOMOTION COMPLETES ENROLLMENT IN PIVOTAL CLINICAL TRIAL FOR BREAK WAVE™ SYSTEM AND SECURES $2.2 MILLION NIH GRANT
April 25, 2025
·
2 min read
Press Releases
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
May 1, 2025
·
1 min read
Press Releases
Early detection is a game changer: Novartis makes bold play to prioritize breast health and inspire a new wave of breast cancer screenings
January 29, 2025
·
11 min read
Huntington’s disease
Takeda Walks Away From Wave Huntington’s Partnership After Sinking $260M in Collaboration
Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on Wave’s WVE-003 clinical-stage Huntington’s disease program—a potential $5 billion commercial opportunity, according to the biotech.
October 16, 2024
·
3 min read
·
Tristan Manalac
Press Releases
New Wave Endo Has Been Recognized on the 2024 Inc. 5000 List of Fastest-Growing Companies and Was the #1 Fastest-Growing Surgical Device Company
August 28, 2024
·
2 min read
Press Releases
Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
May 5, 2025
·
2 min read
1 of 67,649
Next
